aTyr Pharma Inc. (LIFE)’s Financial Results Comparing With Osmotica Pharmaceuticals plc (NASDAQ:OSMT)

aTyr Pharma Inc. (NASDAQ:LIFE) and Osmotica Pharmaceuticals plc (NASDAQ:OSMT) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
aTyr Pharma Inc. N/A 0.00 39.67M -1.33 0.00
Osmotica Pharmaceuticals plc 274.34M 1.50 6.40M -0.13 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
aTyr Pharma Inc. 0.00% -78.1% -53.6%
Osmotica Pharmaceuticals plc -2.33% 0% 0%

Liquidity

5.4 and 5.4 are the respective Current Ratio and a Quick Ratio of aTyr Pharma Inc. Its rival Osmotica Pharmaceuticals plc’s Current and Quick Ratios are 1.3 and 1.1 respectively. aTyr Pharma Inc. has a better chance of clearing its pay short and long-term debts than Osmotica Pharmaceuticals plc.

Analyst Recommendations

aTyr Pharma Inc. and Osmotica Pharmaceuticals plc Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
aTyr Pharma Inc. 0 2 0 2.00
Osmotica Pharmaceuticals plc 0 0 0 0.00

aTyr Pharma Inc. has a consensus target price of $0.88, and a 79.34% upside potential.

Insider & Institutional Ownership

Institutional investors held 55.7% of aTyr Pharma Inc. shares and 37% of Osmotica Pharmaceuticals plc shares. About 0.4% of aTyr Pharma Inc.’s share are held by insiders. On the other hand, insiders held about 41.8% of Osmotica Pharmaceuticals plc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
aTyr Pharma Inc. -6.49% -9.83% -23.17% -41.75% -85.23% -83.54%
Osmotica Pharmaceuticals plc -0.38% -11% 0% 0% 0% -3.68%

For the past year aTyr Pharma Inc. was more bearish than Osmotica Pharmaceuticals plc.

Summary

On 7 of the 10 factors Osmotica Pharmaceuticals plc beats aTyr Pharma Inc.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.